Side-by-side comparison of AI visibility scores, market position, and capabilities
Newport News VA nuclear shipbuilding (NYSE: HII) $11.1B FY2024 revenue; sole US aircraft carrier builder, Virginia/Columbia-class submarine partner, CVN-79 JFK delivery, AUKUS submarines competing with General Dynamics.
Huntington Ingalls Industries, Inc. (HII) is a Newport News, Virginia-based defense shipbuilding and defense services company — publicly traded on the New York Stock Exchange (NYSE: HII) as an S&P 500 Industrials component — building and maintaining nuclear-powered submarines (Virginia-class attack submarines, Columbia-class ballistic missile submarines) and surface ships (Gerald R. Ford-class nuclear aircraft carriers, America-class amphibious assault ships, Arleigh Burke-class destroyers) through its Newport News Shipbuilding and Ingalls Shipbuilding subsidiaries, and providing defense technology and services through the Mission Technologies segment, through approximately 44,000 employees. HII is the largest military shipbuilder in the United States and the sole builder of US Navy nuclear-powered aircraft carriers (Newport News Shipbuilding — Gerald R. Ford-class carriers, the USS Gerald R. Ford CVN-78 delivered 2017, USS John F. Kennedy CVN-79 under construction) and a partner with General Dynamics Electric Boat for Virginia-class nuclear submarine construction (Newport News builds the stern, propulsion systems, and integration; Electric Boat builds the bow and performs final integration at Groton CT). In fiscal year 2024, HII reported revenues of $11.1 billion (+5% year-over-year), with the Shipbuilding segment generating $8.6 billion and Mission Technologies (defense IT, analytics, C5ISR services) generating $2.5 billion. CEO Chris Kastner has focused on improving shipbuilding performance metrics (on-time delivery, ship quality scores, learning curve efficiency) as the Newport News Shipbuilding facilities executed multiple concurrent complex programs — CVN-79 John F. Kennedy carrier construction, CVN-80 Enterprise carrier material purchasing, Virginia-class Block V submarine sections — amid post-COVID skilled shipwright workforce shortages and supply chain disruptions.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.